DZD8586 combined with immunochemotherapy for diffuse large B‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 1/2 trial gives DZD8586 together with one of three immunochemotherapy regimens (R‑CHOP, R‑GemOx, or BR) to patients with diffuse large B‑cell lymphoma to measure safety, objective response rate, and drug levels. Cohort 1 enrolls previously untreated patients with stage II–IV disease, while cohorts 2 and 3 enroll patients who relapsed or are refractory after prior R‑CHOP–like therapy, including those unsuitable for or who refuse transplant. The study's primary outcomes include objective response rate and incidence and severity of adverse events, with pharmacokinetic sampling to measure DZD8586 levels when given with chemotherapy. The trial is being conducted at major hospitals in Beijing, Changsha, and Chengdu, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Cohort 1:

  1. Patients with pathologically confirmed DLBCL who have not received prior anti-lymphoma therapy.
  2. Disease stage II to IV by Ann Arbor Classification.
  3. Life expectancy ≥ 12 months.
* Cohort 2, 3:

  1. Pathologically confirmed DLBCL patients who have received adequate first-line treatment containing CD20 monoclonal antibody and anthracyclines (such as R-CHOP-like regimen).
  2. Relapsed or refractory to first-line R-CHOP-like regimen.
  3. For patients who have received only one line of therapy, if the patient has not received autologous stem cell transplantation, the investigator needs to assess as unsuitable or the patient refuses intensive chemotherapy and hematopoietic stem cell transplantation.
  4. Life expectancy ≥ 6 months.
* Patients must also meet all of the following criteria to be included in this study:

  1. All patients must provide a signed and dated written informed consent prior to any study-specific procedure, sampling, and analysis.
  2. Patients must be ≥ 18 years of age at the time of informed consent.
  3. ECOG status score of 0 to 2.
  4. Presence of at least one radiologically measurable lesion in 2 perpendicular directions as assessed by CT or MRI and a positive lesion on PET/CT scan consistent with a tumor site identified by CT or MRI.
  5. Adequate bone marrow hematopoietic reserve and organ function.
  6. No uncontrolled medical complications.
  7. Patients should be able to follow the relevant requirements of this study for medication and follow-up.
  8. Willing to comply with contraceptive restrictions.

Exclusion Criteria:

* Cohort 2, 3:

  a. Hematopoietic stem cell transplantation, cell therapy, or gene therapy within 90 days prior to first dose. Radiation therapy within 14 days prior to first dose. Chemotherapy and small-molecule targeted therapy were not terminated within 5 half-lives before the first dose; macromolecule drug therapy (such as antibody therapy) was not terminated within 28 days before the first dose.
* All patients should not be included in this study if they have any of the following conditions:

  1. Indolent lymphoma-transformed DLBCL, primary mediastinal lymphoma, lymphoma involving the central nervous system, or DLBCL with MYC and BCL2 rearrangements.
  2. Prior use of BTK inhibitors.
  3. Vaccination with live attenuated vaccines or viral vector vaccines within 4 weeks prior to enrollment.
  4. Currently taking vitamin K antagonists, taking 2 or more antiplatelet/anticoagulant drugs at the same time, drugs/herbs or supplements known to potently induce or inhibit CYP3A enzyme activity, proton pump inhibitor drugs, anti-tumor traditional Chinese medicine or failing to meet the protocol-specified withdrawal time before administration in this study.
  5. Major surgery within 4 weeks or anticipated surgery after the start of this study. Or insufficiently recovered from any toxicity and/or complications of previous intervention.
  6. Clinically significant cardiac disorders. History of thrombotic diseases, stroke or intracranial hemorrhage within 6 months.
  7. Active infectious diseases.
  8. Intractable nausea and vomiting that cannot be well controlled by supportive treatment, chronic gastrointestinal diseases, dysphagia, or previous surgical resection of the intestinal segment may affect the adequate absorption of the drug.
  9. The patient has been diagnosed with other malignant diseases other than B-cell lymphoma within the past 2 years.
  10. Patients with hypersensitivity to DZD8586 drug excipients or other chemical analogues.
  11. Patients with severe or uncontrolled systemic diseases, including poorly controlled hypertension and active bleeding constitution.
  12. Serious medical or psychiatric illness that could affect participation in the study or could compromise the ability to consent
  13. Women who are pregnant or breastfeeding.

Where it's running

• Peking University Third Hospital
  Beijing, China Recruiting
• West China Hospital of Sichuan University
  Chengdu, China Recruiting
• Guangdong Provincial People's Hospital
  Guangzhou, China Recruiting
• Sun Yat-sen University Cancer Center
  Guangzhou, China Recruiting
• Zhujiang Hospital of Southern Medical University
  Guangzhou, China Recruiting
• The Second Affiliated Hospital Zhejiang University School of Medicine
  Hangzhou, China Recruiting

Study contacts

• Principal investigator: Huang — Sun Yat-Sen University Cancer Center
• Study coordinator: Mengling Zhong
• Email: mengling.zhong@dizalpharma.com
• Phone: +86-21-61095852

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Glofitamab combo vs Rituximab combo with chemo for relapsed/refractory DLBCL

  This study tests whether glofitamab with chemotherapy (JS203-GemOx) helps patients with relapsed or refractory DLBCL more than rituximab with chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07808827

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• External beam radiation followed by bispecific antibody therapy for relapsed or refractory DLBCL

  This study tests whether giving targeted radiation first, then bispecific antibodies (epcoritamab or glofitamab), is tolerable for adults with relapsed or refractory diffuse large B-cell lymphoma.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT07528352

• Chidamide maintenance for MRD-positive double-expressor DLBCL in first remission

  This study tests whether giving chidamide as maintenance therapy can help people with double-expressor DLBCL who have complete remission but still have MRD detected in their blood.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07507318

• Cognitive changes in people treated for diffuse large B‑cell lymphoma

  This study tests whether adults with newly diagnosed diffuse large B‑cell lymphoma experience cognitive changes during and after standard chemotherapy.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07443514

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.